nodes	percent_of_prediction	percent_of_DWPC	metapath
Budesonide—CYP3A4—Cytarabine—lymphatic system cancer	0.133	0.318	CbGbCtD
Budesonide—CYP3A4—Teniposide—lymphatic system cancer	0.131	0.313	CbGbCtD
Budesonide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0915	0.219	CbGbCtD
Budesonide—CYP3A4—Vincristine—lymphatic system cancer	0.063	0.151	CbGbCtD
Budesonide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.0015	0.00258	CcSEcCtD
Budesonide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00149	0.00257	CcSEcCtD
Budesonide—Visual impairment—Carmustine—lymphatic system cancer	0.00149	0.00256	CcSEcCtD
Budesonide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00148	0.00255	CcSEcCtD
Budesonide—Fatigue—Fludarabine—lymphatic system cancer	0.00148	0.00254	CcSEcCtD
Budesonide—Constipation—Fludarabine—lymphatic system cancer	0.00147	0.00252	CcSEcCtD
Budesonide—Pain—Fludarabine—lymphatic system cancer	0.00147	0.00252	CcSEcCtD
Budesonide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00146	0.00251	CcSEcCtD
Budesonide—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00145	0.00249	CcSEcCtD
Budesonide—Urethral disorder—Vincristine—lymphatic system cancer	0.00145	0.00249	CcSEcCtD
Budesonide—Eye disorder—Carmustine—lymphatic system cancer	0.00145	0.00248	CcSEcCtD
Budesonide—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00145	0.00248	CcSEcCtD
Budesonide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00144	0.00248	CcSEcCtD
Budesonide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00144	0.00247	CcSEcCtD
Budesonide—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00144	0.00247	CcSEcCtD
Budesonide—Flushing—Carmustine—lymphatic system cancer	0.00144	0.00247	CcSEcCtD
Budesonide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00143	0.00246	CcSEcCtD
Budesonide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00143	0.00245	CcSEcCtD
Budesonide—Anaemia—Bleomycin—lymphatic system cancer	0.00143	0.00245	CcSEcCtD
Budesonide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00141	0.00243	CcSEcCtD
Budesonide—Asthenia—Teniposide—lymphatic system cancer	0.0014	0.00241	CcSEcCtD
Budesonide—Malaise—Bleomycin—lymphatic system cancer	0.00139	0.00239	CcSEcCtD
Budesonide—Pruritus—Teniposide—lymphatic system cancer	0.00138	0.00238	CcSEcCtD
Budesonide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00137	0.00236	CcSEcCtD
Budesonide—Alopecia—Carmustine—lymphatic system cancer	0.00137	0.00235	CcSEcCtD
Budesonide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00136	0.00233	CcSEcCtD
Budesonide—Mental disorder—Carmustine—lymphatic system cancer	0.00136	0.00233	CcSEcCtD
Budesonide—Malnutrition—Carmustine—lymphatic system cancer	0.00135	0.00231	CcSEcCtD
Budesonide—Cough—Bleomycin—lymphatic system cancer	0.00135	0.00231	CcSEcCtD
Budesonide—Angiopathy—Vincristine—lymphatic system cancer	0.00134	0.0023	CcSEcCtD
Budesonide—Diarrhoea—Teniposide—lymphatic system cancer	0.00134	0.0023	CcSEcCtD
Budesonide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00133	0.00229	CcSEcCtD
Budesonide—Chest pain—Bleomycin—lymphatic system cancer	0.00131	0.00226	CcSEcCtD
Budesonide—Myalgia—Bleomycin—lymphatic system cancer	0.00131	0.00226	CcSEcCtD
Budesonide—Alopecia—Vincristine—lymphatic system cancer	0.0013	0.00224	CcSEcCtD
Budesonide—Back pain—Carmustine—lymphatic system cancer	0.0013	0.00224	CcSEcCtD
Budesonide—Discomfort—Bleomycin—lymphatic system cancer	0.0013	0.00223	CcSEcCtD
Budesonide—Mental disorder—Vincristine—lymphatic system cancer	0.00129	0.00222	CcSEcCtD
Budesonide—Ecchymosis—Methotrexate—lymphatic system cancer	0.00129	0.00222	CcSEcCtD
Budesonide—Alopecia—Mitoxantrone—lymphatic system cancer	0.00127	0.00218	CcSEcCtD
Budesonide—Confusional state—Bleomycin—lymphatic system cancer	0.00127	0.00218	CcSEcCtD
Budesonide—Vision blurred—Carmustine—lymphatic system cancer	0.00127	0.00218	CcSEcCtD
Budesonide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00127	0.00217	CcSEcCtD
Budesonide—Tremor—Carmustine—lymphatic system cancer	0.00126	0.00217	CcSEcCtD
Budesonide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00126	0.00216	CcSEcCtD
Budesonide—Infection—Bleomycin—lymphatic system cancer	0.00125	0.00215	CcSEcCtD
Budesonide—Anaemia—Carmustine—lymphatic system cancer	0.00124	0.00214	CcSEcCtD
Budesonide—Back pain—Vincristine—lymphatic system cancer	0.00124	0.00214	CcSEcCtD
Budesonide—Vomiting—Teniposide—lymphatic system cancer	0.00124	0.00214	CcSEcCtD
Budesonide—Agitation—Carmustine—lymphatic system cancer	0.00124	0.00213	CcSEcCtD
Budesonide—Asthenia—Fludarabine—lymphatic system cancer	0.00123	0.00212	CcSEcCtD
Budesonide—Rash—Teniposide—lymphatic system cancer	0.00123	0.00212	CcSEcCtD
Budesonide—Dermatitis—Teniposide—lymphatic system cancer	0.00123	0.00212	CcSEcCtD
Budesonide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00123	0.00211	CcSEcCtD
Budesonide—Headache—Teniposide—lymphatic system cancer	0.00122	0.0021	CcSEcCtD
Budesonide—Pruritus—Fludarabine—lymphatic system cancer	0.00121	0.00209	CcSEcCtD
Budesonide—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00121	0.00209	CcSEcCtD
Budesonide—Back pain—Mitoxantrone—lymphatic system cancer	0.00121	0.00208	CcSEcCtD
Budesonide—Anorexia—Bleomycin—lymphatic system cancer	0.0012	0.00206	CcSEcCtD
Budesonide—Anaemia—Vincristine—lymphatic system cancer	0.00119	0.00204	CcSEcCtD
Budesonide—Agitation—Vincristine—lymphatic system cancer	0.00118	0.00203	CcSEcCtD
Budesonide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00118	0.00203	CcSEcCtD
Budesonide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00117	0.00202	CcSEcCtD
Budesonide—Hypertension—Carmustine—lymphatic system cancer	0.00116	0.002	CcSEcCtD
Budesonide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00116	0.002	CcSEcCtD
Budesonide—Nausea—Teniposide—lymphatic system cancer	0.00116	0.00199	CcSEcCtD
Budesonide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00116	0.00199	CcSEcCtD
Budesonide—Vertigo—Vincristine—lymphatic system cancer	0.00115	0.00198	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00115	0.00197	CcSEcCtD
Budesonide—Chest pain—Carmustine—lymphatic system cancer	0.00115	0.00197	CcSEcCtD
Budesonide—Myalgia—Carmustine—lymphatic system cancer	0.00115	0.00197	CcSEcCtD
Budesonide—Anxiety—Carmustine—lymphatic system cancer	0.00114	0.00196	CcSEcCtD
Budesonide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00113	0.00194	CcSEcCtD
Budesonide—Malaise—Mitoxantrone—lymphatic system cancer	0.00113	0.00194	CcSEcCtD
Budesonide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00112	0.00193	CcSEcCtD
Budesonide—Hypertension—Vincristine—lymphatic system cancer	0.00111	0.00191	CcSEcCtD
Budesonide—Confusional state—Carmustine—lymphatic system cancer	0.00111	0.0019	CcSEcCtD
Budesonide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00109	0.00188	CcSEcCtD
Budesonide—Myalgia—Vincristine—lymphatic system cancer	0.00109	0.00188	CcSEcCtD
Budesonide—Cough—Mitoxantrone—lymphatic system cancer	0.00109	0.00188	CcSEcCtD
Budesonide—Infection—Carmustine—lymphatic system cancer	0.00109	0.00188	CcSEcCtD
Budesonide—Vomiting—Fludarabine—lymphatic system cancer	0.00109	0.00188	CcSEcCtD
Budesonide—Rash—Fludarabine—lymphatic system cancer	0.00108	0.00186	CcSEcCtD
Budesonide—Dermatitis—Fludarabine—lymphatic system cancer	0.00108	0.00186	CcSEcCtD
Budesonide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00108	0.00186	CcSEcCtD
Budesonide—Pain—Bleomycin—lymphatic system cancer	0.00108	0.00185	CcSEcCtD
Budesonide—Headache—Fludarabine—lymphatic system cancer	0.00108	0.00185	CcSEcCtD
Budesonide—Tachycardia—Carmustine—lymphatic system cancer	0.00107	0.00184	CcSEcCtD
Budesonide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00107	0.00183	CcSEcCtD
Budesonide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00107	0.00183	CcSEcCtD
Budesonide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00107	0.00183	CcSEcCtD
Budesonide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00106	0.00183	CcSEcCtD
Budesonide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00105	0.00181	CcSEcCtD
Budesonide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00105	0.0018	CcSEcCtD
Budesonide—Anorexia—Carmustine—lymphatic system cancer	0.00105	0.0018	CcSEcCtD
Budesonide—Infection—Vincristine—lymphatic system cancer	0.00104	0.00179	CcSEcCtD
Budesonide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00104	0.00178	CcSEcCtD
Budesonide—Confusional state—Mitoxantrone—lymphatic system cancer	0.00103	0.00177	CcSEcCtD
Budesonide—Nervous system disorder—Vincristine—lymphatic system cancer	0.00103	0.00177	CcSEcCtD
Budesonide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00102	0.00176	CcSEcCtD
Budesonide—Nausea—Fludarabine—lymphatic system cancer	0.00102	0.00175	CcSEcCtD
Budesonide—Infection—Mitoxantrone—lymphatic system cancer	0.00101	0.00174	CcSEcCtD
Budesonide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00101	0.00174	CcSEcCtD
Budesonide—Shock—Mitoxantrone—lymphatic system cancer	0.00101	0.00173	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.001	0.00172	CcSEcCtD
Budesonide—Urticaria—Bleomycin—lymphatic system cancer	0.001	0.00172	CcSEcCtD
Budesonide—Anorexia—Vincristine—lymphatic system cancer	0.001	0.00172	CcSEcCtD
Budesonide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000997	0.00171	CcSEcCtD
Budesonide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000995	0.00171	CcSEcCtD
Budesonide—Insomnia—Carmustine—lymphatic system cancer	0.000994	0.00171	CcSEcCtD
Budesonide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000992	0.00171	CcSEcCtD
Budesonide—Irritability—Methotrexate—lymphatic system cancer	0.000988	0.0017	CcSEcCtD
Budesonide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000988	0.0017	CcSEcCtD
Budesonide—Paraesthesia—Carmustine—lymphatic system cancer	0.000987	0.0017	CcSEcCtD
Budesonide—Mood swings—Methotrexate—lymphatic system cancer	0.000981	0.00169	CcSEcCtD
Budesonide—Dyspnoea—Carmustine—lymphatic system cancer	0.00098	0.00168	CcSEcCtD
Budesonide—Somnolence—Carmustine—lymphatic system cancer	0.000977	0.00168	CcSEcCtD
Budesonide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000974	0.00167	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000956	0.00164	CcSEcCtD
Budesonide—Decreased appetite—Carmustine—lymphatic system cancer	0.000955	0.00164	CcSEcCtD
Budesonide—Insomnia—Vincristine—lymphatic system cancer	0.000949	0.00163	CcSEcCtD
Budesonide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000949	0.00163	CcSEcCtD
Budesonide—Paraesthesia—Vincristine—lymphatic system cancer	0.000942	0.00162	CcSEcCtD
Budesonide—Pain—Carmustine—lymphatic system cancer	0.00094	0.00162	CcSEcCtD
Budesonide—Constipation—Carmustine—lymphatic system cancer	0.00094	0.00162	CcSEcCtD
Budesonide—Breast disorder—Methotrexate—lymphatic system cancer	0.000936	0.00161	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000931	0.0016	CcSEcCtD
Budesonide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000928	0.00159	CcSEcCtD
Budesonide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000917	0.00158	CcSEcCtD
Budesonide—Decreased appetite—Vincristine—lymphatic system cancer	0.000912	0.00157	CcSEcCtD
Budesonide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000911	0.00157	CcSEcCtD
Budesonide—Somnolence—Mitoxantrone—lymphatic system cancer	0.000908	0.00156	CcSEcCtD
Budesonide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000906	0.00156	CcSEcCtD
Budesonide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000906	0.00156	CcSEcCtD
Budesonide—Fatigue—Vincristine—lymphatic system cancer	0.000904	0.00155	CcSEcCtD
Budesonide—Asthenia—Bleomycin—lymphatic system cancer	0.000903	0.00155	CcSEcCtD
Budesonide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000899	0.00155	CcSEcCtD
Budesonide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000899	0.00154	CcSEcCtD
Budesonide—Pain—Vincristine—lymphatic system cancer	0.000897	0.00154	CcSEcCtD
Budesonide—Constipation—Vincristine—lymphatic system cancer	0.000897	0.00154	CcSEcCtD
Budesonide—Pruritus—Bleomycin—lymphatic system cancer	0.000891	0.00153	CcSEcCtD
Budesonide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000888	0.00153	CcSEcCtD
Budesonide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000881	0.00151	CcSEcCtD
Budesonide—Constipation—Mitoxantrone—lymphatic system cancer	0.000874	0.0015	CcSEcCtD
Budesonide—Pain—Mitoxantrone—lymphatic system cancer	0.000874	0.0015	CcSEcCtD
Budesonide—Abdominal pain—Carmustine—lymphatic system cancer	0.000869	0.00149	CcSEcCtD
Budesonide—Body temperature increased—Carmustine—lymphatic system cancer	0.000869	0.00149	CcSEcCtD
Budesonide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000858	0.00147	CcSEcCtD
Budesonide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000842	0.00145	CcSEcCtD
Budesonide—Dysuria—Methotrexate—lymphatic system cancer	0.000837	0.00144	CcSEcCtD
Budesonide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000835	0.00144	CcSEcCtD
Budesonide—Body temperature increased—Vincristine—lymphatic system cancer	0.000829	0.00143	CcSEcCtD
Budesonide—Abdominal pain—Vincristine—lymphatic system cancer	0.000829	0.00143	CcSEcCtD
Budesonide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000812	0.0014	CcSEcCtD
Budesonide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00081	0.00139	CcSEcCtD
Budesonide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000808	0.00139	CcSEcCtD
Budesonide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000808	0.00139	CcSEcCtD
Budesonide—Vomiting—Bleomycin—lymphatic system cancer	0.0008	0.00138	CcSEcCtD
Budesonide—Infestation NOS—Methotrexate—lymphatic system cancer	0.000798	0.00137	CcSEcCtD
Budesonide—Infestation—Methotrexate—lymphatic system cancer	0.000798	0.00137	CcSEcCtD
Budesonide—Rash—Bleomycin—lymphatic system cancer	0.000794	0.00136	CcSEcCtD
Budesonide—Dermatitis—Bleomycin—lymphatic system cancer	0.000793	0.00136	CcSEcCtD
Budesonide—Asthenia—Carmustine—lymphatic system cancer	0.000788	0.00136	CcSEcCtD
Budesonide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000776	0.00133	CcSEcCtD
Budesonide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000773	0.00133	CcSEcCtD
Budesonide—Haematuria—Methotrexate—lymphatic system cancer	0.000761	0.00131	CcSEcCtD
Budesonide—Epistaxis—Methotrexate—lymphatic system cancer	0.000753	0.00129	CcSEcCtD
Budesonide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000753	0.00129	CcSEcCtD
Budesonide—Asthenia—Vincristine—lymphatic system cancer	0.000753	0.00129	CcSEcCtD
Budesonide—Diarrhoea—Carmustine—lymphatic system cancer	0.000752	0.00129	CcSEcCtD
Budesonide—Nausea—Bleomycin—lymphatic system cancer	0.000748	0.00129	CcSEcCtD
Budesonide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000733	0.00126	CcSEcCtD
Budesonide—Dizziness—Carmustine—lymphatic system cancer	0.000727	0.00125	CcSEcCtD
Budesonide—Haemoglobin—Methotrexate—lymphatic system cancer	0.00072	0.00124	CcSEcCtD
Budesonide—Diarrhoea—Vincristine—lymphatic system cancer	0.000718	0.00123	CcSEcCtD
Budesonide—Haemorrhage—Methotrexate—lymphatic system cancer	0.000716	0.00123	CcSEcCtD
Budesonide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000711	0.00122	CcSEcCtD
Budesonide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000708	0.00122	CcSEcCtD
Budesonide—Urethral disorder—Methotrexate—lymphatic system cancer	0.000702	0.00121	CcSEcCtD
Budesonide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000699	0.0012	CcSEcCtD
Budesonide—Vomiting—Carmustine—lymphatic system cancer	0.000699	0.0012	CcSEcCtD
Budesonide—Dizziness—Vincristine—lymphatic system cancer	0.000694	0.00119	CcSEcCtD
Budesonide—Rash—Carmustine—lymphatic system cancer	0.000693	0.00119	CcSEcCtD
Budesonide—Dermatitis—Carmustine—lymphatic system cancer	0.000692	0.00119	CcSEcCtD
Budesonide—Visual impairment—Methotrexate—lymphatic system cancer	0.00069	0.00119	CcSEcCtD
Budesonide—Headache—Carmustine—lymphatic system cancer	0.000688	0.00118	CcSEcCtD
Budesonide—Eye disorder—Methotrexate—lymphatic system cancer	0.00067	0.00115	CcSEcCtD
Budesonide—Vomiting—Vincristine—lymphatic system cancer	0.000667	0.00115	CcSEcCtD
Budesonide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000665	0.00114	CcSEcCtD
Budesonide—Rash—Vincristine—lymphatic system cancer	0.000661	0.00114	CcSEcCtD
Budesonide—Dermatitis—Vincristine—lymphatic system cancer	0.000661	0.00114	CcSEcCtD
Budesonide—Headache—Vincristine—lymphatic system cancer	0.000657	0.00113	CcSEcCtD
Budesonide—Nausea—Carmustine—lymphatic system cancer	0.000653	0.00112	CcSEcCtD
Budesonide—Angiopathy—Methotrexate—lymphatic system cancer	0.00065	0.00112	CcSEcCtD
Budesonide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00065	0.00112	CcSEcCtD
Budesonide—Immune system disorder—Methotrexate—lymphatic system cancer	0.000647	0.00111	CcSEcCtD
Budesonide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000646	0.00111	CcSEcCtD
Budesonide—Rash—Mitoxantrone—lymphatic system cancer	0.000644	0.00111	CcSEcCtD
Budesonide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000644	0.00111	CcSEcCtD
Budesonide—Headache—Mitoxantrone—lymphatic system cancer	0.00064	0.0011	CcSEcCtD
Budesonide—Alopecia—Methotrexate—lymphatic system cancer	0.000633	0.00109	CcSEcCtD
Budesonide—Mental disorder—Methotrexate—lymphatic system cancer	0.000628	0.00108	CcSEcCtD
Budesonide—Malnutrition—Methotrexate—lymphatic system cancer	0.000624	0.00107	CcSEcCtD
Budesonide—Nausea—Vincristine—lymphatic system cancer	0.000623	0.00107	CcSEcCtD
Budesonide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000611	0.00105	CcSEcCtD
Budesonide—Nausea—Mitoxantrone—lymphatic system cancer	0.000607	0.00104	CcSEcCtD
Budesonide—Back pain—Methotrexate—lymphatic system cancer	0.000603	0.00104	CcSEcCtD
Budesonide—Vision blurred—Methotrexate—lymphatic system cancer	0.000588	0.00101	CcSEcCtD
Budesonide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000579	0.000995	CcSEcCtD
Budesonide—Anaemia—Methotrexate—lymphatic system cancer	0.000576	0.000991	CcSEcCtD
Budesonide—Malaise—Methotrexate—lymphatic system cancer	0.000562	0.000967	CcSEcCtD
Budesonide—Vertigo—Methotrexate—lymphatic system cancer	0.00056	0.000963	CcSEcCtD
Budesonide—Cough—Methotrexate—lymphatic system cancer	0.000544	0.000935	CcSEcCtD
Budesonide—Chest pain—Methotrexate—lymphatic system cancer	0.000531	0.000913	CcSEcCtD
Budesonide—Arthralgia—Methotrexate—lymphatic system cancer	0.000531	0.000913	CcSEcCtD
Budesonide—Myalgia—Methotrexate—lymphatic system cancer	0.000531	0.000913	CcSEcCtD
Budesonide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000527	0.000906	CcSEcCtD
Budesonide—Discomfort—Methotrexate—lymphatic system cancer	0.000525	0.000902	CcSEcCtD
Budesonide—Confusional state—Methotrexate—lymphatic system cancer	0.000513	0.000882	CcSEcCtD
Budesonide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000509	0.000875	CcSEcCtD
Budesonide—Infection—Methotrexate—lymphatic system cancer	0.000506	0.000869	CcSEcCtD
Budesonide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000499	0.000858	CcSEcCtD
Budesonide—Skin disorder—Methotrexate—lymphatic system cancer	0.000494	0.00085	CcSEcCtD
Budesonide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000492	0.000846	CcSEcCtD
Budesonide—Anorexia—Methotrexate—lymphatic system cancer	0.000485	0.000834	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000464	0.000797	CcSEcCtD
Budesonide—Insomnia—Methotrexate—lymphatic system cancer	0.00046	0.000791	CcSEcCtD
Budesonide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000457	0.000786	CcSEcCtD
Budesonide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000454	0.00078	CcSEcCtD
Budesonide—Somnolence—Methotrexate—lymphatic system cancer	0.000453	0.000778	CcSEcCtD
Budesonide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000448	0.00077	CcSEcCtD
Budesonide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000442	0.000761	CcSEcCtD
Budesonide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000439	0.000755	CcSEcCtD
Budesonide—Fatigue—Methotrexate—lymphatic system cancer	0.000439	0.000754	CcSEcCtD
Budesonide—Pain—Methotrexate—lymphatic system cancer	0.000435	0.000748	CcSEcCtD
Budesonide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000419	0.000721	CcSEcCtD
Budesonide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000416	0.000715	CcSEcCtD
Budesonide—Urticaria—Methotrexate—lymphatic system cancer	0.000404	0.000695	CcSEcCtD
Budesonide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000402	0.000692	CcSEcCtD
Budesonide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000402	0.000692	CcSEcCtD
Budesonide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000375	0.000645	CcSEcCtD
Budesonide—Asthenia—Methotrexate—lymphatic system cancer	0.000365	0.000628	CcSEcCtD
Budesonide—Pruritus—Methotrexate—lymphatic system cancer	0.00036	0.000619	CcSEcCtD
Budesonide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000348	0.000599	CcSEcCtD
Budesonide—Dizziness—Methotrexate—lymphatic system cancer	0.000337	0.000579	CcSEcCtD
Budesonide—Vomiting—Methotrexate—lymphatic system cancer	0.000324	0.000556	CcSEcCtD
Budesonide—Rash—Methotrexate—lymphatic system cancer	0.000321	0.000552	CcSEcCtD
Budesonide—Dermatitis—Methotrexate—lymphatic system cancer	0.000321	0.000551	CcSEcCtD
Budesonide—Headache—Methotrexate—lymphatic system cancer	0.000319	0.000548	CcSEcCtD
Budesonide—Nausea—Methotrexate—lymphatic system cancer	0.000302	0.00052	CcSEcCtD
